Study on Glofitamab Alone and with Chemoimmunotherapy for Children and Young Adults with Relapsed or Hard-to-Treat B-Cell Non-Hodgkin Lymphoma

Inclusion Criteria

• Age between 6 months and under 18 years for Part 1 and Cohort B, and between 6 months and 30 years for Part 2.
• Confirmed diagnosis of aggressive B-cell Non-Hodgkin Lymphoma that shows the CD20 marker, including specific types like Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma.
• Cancer that has not responded to initial treatment or has returned after treatment.
• At least one tumor that can be measured by scans or a certain percentage of cancer cells in the bone marrow.
• Good overall health as measured by specific performance scales.
• Healthy bone marrow, liver, and kidney function.
• Negative tests for hepatitis B, hepatitis C, and HIV, unless HIV is well-controlled.
• Negative COVID-19 test within 7 days before joining the study.
• Willingness of participants and caregivers to complete study assessments.

Exclusion Criteria

• Cancer only in the central nervous system (CNS) without affecting other parts of the body.
• Previous treatment with glofitamab.
• Ongoing severe side effects from past cancer treatments.
• Active infections not resolved before starting the study.
• Previous organ transplant.
• History of certain immune system disorders or chronic viral infections.
• Active autoimmune diseases needing treatment.
• Severe allergic reactions to similar treatments in the past.
• History of certain brain diseases or conditions.
• Major surgery or injury within 28 days before starting the study treatment.
• Recent live vaccine within 4 weeks before starting the study treatment or during the study.